Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1002535-21-8 | MDL No. : | MFCD06739075 |
Formula : | C10H8N2O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | BXSUQWZHUHROLP-UHFFFAOYSA-N |
M.W : | 188.18 | Pubchem ID : | 7174253 |
Synonyms : |
|
Num. heavy atoms : | 14 |
Num. arom. heavy atoms : | 11 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 2 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 50.98 |
TPSA : | 65.98 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.48 cm/s |
Log Po/w (iLOGP) : | 0.79 |
Log Po/w (XLOGP3) : | 1.37 |
Log Po/w (WLOGP) : | 1.77 |
Log Po/w (MLOGP) : | 1.03 |
Log Po/w (SILICOS-IT) : | 1.92 |
Consensus Log Po/w : | 1.38 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.85 |
Log S (ESOL) : | -2.32 |
Solubility : | 0.902 mg/ml ; 0.00479 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.36 |
Solubility : | 0.824 mg/ml ; 0.00438 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.13 |
Solubility : | 0.14 mg/ml ; 0.000745 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.86 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P264-P270-P301+P312-P330 | UN#: | N/A |
Hazard Statements: | H302 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
67% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane for 4h; Inert atmosphere; | 31 Example 31: 1-(3-(1H-Pyrazol-4-yl)benzoyl)-N-(4-chlorophenyl)piperidine-3- carboxamide [00184] To a solution of carboxylic acid (0.047g, 0.25 mmole), DMAP (6 mg, 0.05 mmole) and piperidine derivative (0.06 g, 0.25 mmole) in DCM (3 mL) was added EDC (0.053 g, 0.28 mmole). The reaction mixture was stuffed under N2 for 4h. TLC indicated disappearance of the starting materials. The reaction mixture was extracted with saturated NaHCO3 (2 mL), 10% KHSO4 (1 mL) and water (2 x 2 mL). The solution was dried(NaSO4) and the solvent was removed under reduced pressure to give the product. The crude compound was purified by column chromatography eluting with 60 - 100% EtOAc/hexanes over 500 mL. Fractions were pooled after checking TLC. The solvent was removed under reduced pressure to give the title compound (0.069g, 67%) in pure form. ‘H NMR (400 MHz, CDC13, 56 °C) ö 9.07, 7.82, 7.64- 7.54, 7.49, 7.40, 7.27 - 7.19, 4.19 - 3.27, 2.68, 2.25, 1.95 & 1.71 - 1.43. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
15% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 20℃; | 51 Example 51: (3-(1H-pyrazol-4-yl)phenyl)(5-((4-chlorophenoxy)methyl)-3,3- difluoropiperidin-1-yl)methanone [00226] To a solution of 5-((4-chlorophenoxy)methyl)-3,3-difluoropiperidine (48 mg, 0.18 mmol) in THF (2 ml) was added 3-(1H-pyrazol-4-yl)benzoic acid (34 mg, 0.18 mmol), N-(3- dimethylaminopropyl)-N ‘-ethylcarbodiimide hydrochloride (53 mg, 0.28 mmol), N,Ndiisopropylethylamine (0.096 ml, 0.55 mmol), and 4-(dimethylamino)pyridine (4.5 mg, 0.037 mmol). The reaction stuffed at room temperature overnight. The reaction was diluted with ethyl acetate and washed with saturated sodium carbonate solution and brine. The organic layer was dried over magnesium sulfate, filtered, and concentrated. The crude residue was purified by column chromatography eluting with 0-5% methanol in dichloromethane to afford the title compound as a white amorphous solid (12 mg, yield 15%). ‘H NMR (400 MHz, CDC13, 55 °C) ö 10.39, 7.84, 7.56, 7.41, 7.27, 7.22, 7.67, 4.38, 4.25, 3.91, 3.40, 3.08, 2.45, 2.35, 1.99. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In tetrahydrofuran |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In tetrahydrofuran |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With N-ethyl-N,N-diisopropylamine; HATU In N,N-dimethyl-formamide at 20℃; for 4h; | Final coupling: compounds 11, 20-29 General procedure: (S)-2-amino-N-(1-cyanocyclopropyl)-3-(pyridin-3-yl)propanamide (1 Eq.) acid (1 Eq.) and HATU (1.2 Eq.) were dissolved in DMF (0.145 M). DIPEA (4 Eq.) was added dropwise at room temperature and mixture stirred for 4H. The mixture was charged on a Si-CO3 cartridge (2 g) and eluted with MeOH. Volatiles were removed and crude purified by preparative Rp HPLC (MeCN/Water + 0.1% TFA). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Stage #1: indium(III) chloride With sodium tetrahydroborate In water at -1℃; Stage #2: 3-(1-H-pyrazole-4-yl)benzoic acid In water at -1℃; for 38.5h; Sonication; | 2.1-2.2 Add 64ml of polyvinyl alcohol aqueous solution (concentration 0.1g/ml, of which polyethylene is 0.145mol),Add 3.75ml indium trichloride aqueous solution (concentration 0.8g/ml,Among them, 0.016mol of indium), stir at -1°C for 1.5h; keep stirring,To the above solution was added 37.344g of freshly prepared NaBH4 aqueous solution (concentration 9wt%,Among them, NaBH 40.09 mol) to form PVA-In nanosol;2) Disperse 3.952g/0.021mol 3-(1H-pyrazol-4-yl)benzoic acid in 39.517ml water, sonicate (frequency 1750Hz) for 33h, and then add it to the PVA-In nanosol prepared in step 1). Continue to stir at -1°C for 5.5 hours, then centrifuge, wash with deionized water 4 times,Dry at 100°C for 4 hours, then transfer to a roasting furnace and roast at 410°C for 4 hours,An In-MOF catalyst is obtained. (The mass fraction of indium in the catalyst is about 17.985wt%) |
[ 1017794-47-6 ]
4-(1H-Pyrazol-4-yl)benzoic acid
Similarity: 1.00
[ 1187931-83-4 ]
3-(1H-Pyrazol-4-yl)benzoic acid hydrochloride
Similarity: 0.98
[ 1017794-45-4 ]
4-(1H-Pyrazol-4-yl)benzaldehyde
Similarity: 0.86
[ 1017794-46-5 ]
3-(1H-Pyrazol-4-yl)benzaldehyde
Similarity: 0.86
[ 185252-69-1 ]
4-(3,5-Dimethyl-1H-pyrazol-4-yl)benzoic acid
Similarity: 0.81
[ 1017794-47-6 ]
4-(1H-Pyrazol-4-yl)benzoic acid
Similarity: 1.00
[ 1187931-83-4 ]
3-(1H-Pyrazol-4-yl)benzoic acid hydrochloride
Similarity: 0.98
[ 1183147-84-3 ]
3-(1-Methyl-1H-pyrazol-4-yl)benzoic acid
Similarity: 0.81
[ 185252-69-1 ]
4-(3,5-Dimethyl-1H-pyrazol-4-yl)benzoic acid
Similarity: 0.81
[ 199678-06-3 ]
4-(1-Methyl-1H-pyrazol-4-yl)benzoic acid
Similarity: 0.81
[ 1017794-47-6 ]
4-(1H-Pyrazol-4-yl)benzoic acid
Similarity: 1.00
[ 1187931-83-4 ]
3-(1H-Pyrazol-4-yl)benzoic acid hydrochloride
Similarity: 0.98
[ 1017794-45-4 ]
4-(1H-Pyrazol-4-yl)benzaldehyde
Similarity: 0.86
[ 1017794-46-5 ]
3-(1H-Pyrazol-4-yl)benzaldehyde
Similarity: 0.86
[ 185252-69-1 ]
4-(3,5-Dimethyl-1H-pyrazol-4-yl)benzoic acid
Similarity: 0.81